Bausch Health Launches ENVIVE Daily Probiotic Supplement

Proprietary Blend of Five Live Probiotic Strains Shown to Help Reduce Severity and Frequency of Common, Occasional GI Symptoms*

Now Rolling out to Major U.S. Retailers

- Bausch Health Companies Inc. (NYSETSX: BHC) ("Bausch Health") today announced the U.S. launch of its novel daily over-the-counter probiotic supplement, ENVIVE™. ENVIVE™ is shown to help reduce the severity and frequency of five occasional gastrointestinal (GI) symptoms - diarrhea, constipation, gas, bloating and discomfort - and help strengthen and protect the digestive system by strengthening the gut barrier. ENVIVE™ is proven to help relieve these occasional GI symptoms in as little as two weeks.*

"The launch of ENVIVE™ is another key example of Bausch Health's continued focus on bringing new products to market that help fulfill patients' needs," said Joseph C. Papa , chairman and CEO, Bausch Health . "Research indicates that approximately 61% of Americans have experienced one or more GI symptoms in the past week. 1 Leveraging our scientific knowledge and legacy of innovation in GI research, we specifically developed and clinically tested ENVIVE™ to offer consumers a new preservative-free, multi-strain probiotic designed to help relieve five occasional GI symptoms."

In a healthy gut, probiotics or live organisms, help maintain a healthy balance of "good" and "bad" bacteria. Stress and poor diet, among other causes, can disrupt this balance, which can negatively affect overall digestive health. Probiotic supplements contain "good" bacteria that, when consumed, can help restore the balance and may help protect the GI tract from harmful microorganisms that can negatively affect digestion and gut function. In a four-week study, participants taking ENVIVE™ experienced a reduction in the severity and frequency of five occasional GI symptoms at both weeks two and four, and 85% reported improved overall GI well-being. ENVIVE™ was also shown to help strengthen the gut barrier.

"Many of my patients experience common, occasional GI disturbances due to stress, poor diet or other lifestyle factors, particularly in today's difficult times," said Reed B. Hogan, II , M.D., a gastroenterologist from GI Associates & Endoscopy Center, Flowood, Miss. "Only ENVIVE™ has this unique blend of five clinically studied probiotic strains that have been shown to help strengthen the digestive system and reduce occasional GI symptoms."*

ENVIVE™ will be available for purchase at most national retailers, including Target, CVS, Kroger, Walmart, Rite Aid and Amazon, and will have a manufacturer's suggested retail price of $16.99 (15-count).

About Bausch Health
Bausch Health Companies Inc. (NYSE/TSX: BHC) is a global company whose mission is to improve people's lives with our health care products. We develop, manufacture and market a range of pharmaceutical, medical device and over-the-counter products, primarily in the therapeutic areas of eye health, gastroenterology and dermatology. We are delivering on our commitments as we build an innovative company dedicated to advancing global health. More information can be found at www.bauschhealth.com .

Forward-looking Statements
This news release may contain forward-looking statements, which may generally be identified by the use of the words "anticipates," "expects," "intends," "plans," "should," "could," "would," "may," "believes," "estimates," "potential," "target," or "continue" and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, the risks and uncertainties discussed in Bausch Health's most recent annual report on Form 10-K and detailed from time to time in Bausch Health's other filings with the U.S. Securities and Exchange Commission and the Canadian Securities Administrators, which factors are incorporated herein by reference. They also include, but are not limited to, risks and uncertainties caused by or relating to the evolving COVID-19 pandemic, and the fear of that pandemic and its potential effects, the severity, duration and future impact of which are highly uncertain and cannot be predicted, and which may have a material adverse impact on Bausch Health, including but not limited to its project development timelines, and costs (which may increase). Readers are cautioned not to place undue reliance on any of these forward-looking statements. These forward-looking statements speak only as of the date hereof. Bausch Health undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this news release or to reflect actual outcomes, unless required by law.

* These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.

References

  1. Almario CV, Ballal ML, Chey WD, et al. Burden of gastrointestinal symptoms in the United States : results of a nationally representative survey of over 71,000 Americans. Am J Gastroenterol. 2018;113(11):1701-1710. doi:10.1038/s41395-018-0256-8.

®/   TM are trademarks of Bausch Health Companies Inc. or its affiliates.
Any other product/brand names and/or logos are trademarks of the respective owners.
  © 2021 Bausch Health Companies Inc. or its affiliates.
  ENV.0040.USA.21

Investor Contact:

Media Contact:

Arthur Shannon

Lainie Keller

arthur.shannon@bauschhealth.com

lainie.keller@bauschhealth.com

(514) 856-3855

(908) 927-1198

(877) 281-6642 (toll free)


Bausch Health logo (PRNewsfoto/Bausch Health Companies Inc.)

Cision View original content to download multimedia: https://www.prnewswire.com/news-releases/bausch-health-launches-envive-daily-probiotic-supplement-301264738.html

SOURCE Bausch Health Companies Inc.

News Provided by PR Newswire via QuoteMedia

The Conversation (0)
Bausch Health Companies Inc.

Bausch Health Companies Inc.

Formerly known as Valeant Pharmaceuticals, Bausch Health is a global specialty pharmaceutical, consumer health, and medical device company with a focus on branded products for the dermatology, gastrointestinal, and ophthalmology markets. The company reports revenue in five segments: Bausch+Lomb (45% of revenue), Salix Pharmaceuticals (24%), international pharma (14%), ortho dermatology (7%), and diversified products (10%). Bausch is the market leader in consumer visioncare in India and China and the fourth-largest visioncare company by sales in the United States.

illustration of brain and cell phone.

BlinkLab Completes First Patient Test for US Autism Diagnostic Study

Digital healthcare company BlinkLab (ASX:BB1) has tested the first patient in its US autism diagnostic study, which is geared at validating the company's Dx1 test as a diagnostic aid for clinicians.

BlinkLab states in its Wednesday (March 12) release that the study is the largest digital diagnostic trial for autism in the US, with its aim being to support the early detection of developmental conditions like autism.

The first patient test took place at PriMED Clinical Research in Dayton, Ohio. PriMED, a division of PriMED Physicians, is one of two clinical sites selected for the study’s initial phase, which is targeting 100 patients.

Keep reading...Show less
HeraMED Signs Strategic Collaboration Agreement with Garmin Health

HeraMED Signs Strategic Collaboration Agreement with Garmin Health

HeraMED Limited (ASX: HMD), a medical data and technology company leading the digital transformation of maternity care, is delighted to announce it has entered into a collaboration agreement with Garmin (NYSE: GRMN), a leading global provider of smartwatches and GPS-enabled products, aimed at enhancing remote pregnancy monitoring and expanding the range of health data available to expectant mothers and their healthcare providers.

Keep reading...Show less
Cardiologist wearing virtual reality glasses.

2 Biggest Medical Device ETFs in 2025

Exchange-traded funds (ETFs) are a popular investment strategy, and generally contain a variety of publicly traded companies under one stock symbol, often with a focus on a specific sector.

Depending on the ETF, investors may be able to track up-and-coming companies, get exposure to top firms or a mix of both. Aside from stocks, some ETFs also track commodities or bonds.

In the healthcare industry, medical device ETFs bring together companies that go to great lengths to develop pharmaceutical-based technology that can improve the lives of patients.

Keep reading...Show less
Cyclomedica

Cyclopharm Signs US Agreement with HCA Healthcare for Technegas®

Cyclopharm Limited (ASX: CYC) is pleased to announce the signing of a major contract with Hospital Corporation of America Healthcare (HCA), one of the largest single healthcare providers in the United States. This agreement marks a significant milestone for the company which will allow the deployment of Technegas® in up to 169 nuclear medicine departments across HCA’s extensive network.1

Keep reading...Show less
CONNEQT App Launches in USA as Pulse Deliveries Commence

CONNEQT App Launches in USA as Pulse Deliveries Commence

Cardiex Limited (CDX:AU) has announced CONNEQT App Launches in USA as Pulse Deliveries Commence

Download the PDF here.

Female doctor with clipboard talking to smiling female patient at hospital.

Revolutionizing Women's Health: Antifungal Innovation Brings New Investment Opportunities

The intersection of women's health and antifungal innovation represents a pivotal moment in healthcare, offering both transformative medical advancements and compelling investment opportunities.

The groundbreaking developments in antifungal treatments specifically targeting women's health issues present a substantial market potential, resulting in rising investor interest in this rapidly evolving sector.

Despite comprising half the global population, women face unique health challenges that have historically received insufficient attention and investment. Among these health challenges, vaginal candidiasis stands out as a persistent and widespread issue affecting millions of women worldwide.

Keep reading...Show less

Latest Press Releases

Related News

×